Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yessir absolutely
In other words you’re confident about this one from the clinical stage drug discovery sector
Not for long
AQST................................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
AQST...........................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
AQST.....................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
AQST..EXIT...MASSIVE PLAY
AQST...BREAKING 4 BUCKS...BEAST
AQST monster bio by the master trend
AQST.......................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
Just the beginning
Initiating this one. Fantastic turnaround by company leadership. Look at the ER from last night and see for yourself.
Toxic slobs is more like it.
On going S-3 shelf placement!
AQST
Aquestive Therapeutics Announces EPIPHAST II Trial Data For AQST-109; Says 'AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen Tmax of 22.5 minutes'
7:05 am ET September 27, 2022 (Benzinga) Print
AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes
AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration
Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen
End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter
Company hosts conference call at 8:00 am ET on September 27, 2022
me=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
Quite the hair cut since the delay. I bought in at 4.38 and will buy more if it drops further
Aquestive Therapeutics price target lowered to $7 from $10 at Lake Street
Aquestive Therapeutics price target lowered to $7 from $8 at RBC Capital »
Aquestive Therapeutics price target lowered to $13 from $18 at BMO Capital 07:00 AQST BMO Capital analyst Gary Nachman lowered the firm's price target on Aquestive Therapeutics to $13 from $18 but keeps an Outperform rating on the shares. The analyst notes that the CRL for the company's key product Libervant announced by the FDA on Friday is "disappointing, but should be very fixable" in the near term. Nachman adds that Aquestive intends to resubmit the study by the end of the year and expects a PDUFA date for the drug in the first half of 2021.
Read more at:
https://thefly.com/n.php?id=3166457
Aquestive Therapeutics price target lowered to $17 from $23 at JMP
Aquestive Therapeutics price target lowered to $17 from $23 at JMP Securities 06:07 AQST JMP Securities analyst Jason Butler lowered the firm's price target on Aquestive Therapeutics to $17 from $23 but keeps an Outperform rating on the shares. The analyst notes that the company's announcement of an FDA CRL for Libervant announced on Friday is disappointing, but he believes that the path to approval remains "timely and low risk". Butler adds that his probability of approval for the drug remains at 85%, though his model pushes back assumptions for its launch and first sales by one year to 2021.
Read more at:
https://thefly.com/n.php?id=3166393Securities »
https://thefly.com/news.php?symbol=AQST
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
197
|
Created
|
11/07/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |